HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy
Radovic-Moreno, Aleksandar F.
Wang, Andrew Z.
Marein, Shawn L.
Molnar, Linda K.
MetadataShow full item record
CitationAlexis, Frank, Pamela Basto, Etgar Levy-Nissenbaum, Aleksandar F. Radovic-Moreno, Liangfang Zhang, Eric Pridgen, Andrew Z. Wang, et al. 2008. “HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy.” ChemMedChem 3 (12) (December 15): 1839–1843. doi:10.1002/cmdc.200800122.
AbstractAffibodies are a class of polypeptide ligands that are potential candidates for cell- or tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). Here we report the development of drug delivery vehicles comprised of polymeric NPs that are surface modified with Affibody ligands that bind to the extracellular domain of the trans-membrane human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells which over express the HER-2 antigen. NPs lacking the anti-HER-2 Affibody did not show significant uptake by these cells. Using paclitaxel encapsulated NP-Affibody (1 wt% drug loading), we demonstrated increased cytotoxicity of these bioconjugates in SK-BR-3 and SKOV-3 cell lines. These targeted, drug encapsulated NPAffibody bioconjugates may be efficacious in treating HER-2 expressing carcinoma.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29005176
- HMS Scholarly Articles